Back to top
more

Vivos Therapeutics (VVOS)

(Delayed Data from NSDQ)

$3.44 USD

3.44
249,755

+0.10 (2.99%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $3.44 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 245)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +4.84% and +26.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +218.52% and +66.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of -2.27% and 18.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of -22.22% and 40.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Vivos Therapeutics (VVOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of 34.88% and 5.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates

by Zacks Equity Research

Journey Medical (DERM) delivered earnings and revenue surprises of 136.36% and 1.84%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

VAXART (VXRT) delivered earnings and revenue surprises of 50% and 51.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amneal Pharmaceuticals (AMRX) Q4 Earnings Lag Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of -20% and 3.15%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Best Momentum Stocks to Buy for January 8th

by Zacks Equity Research

VVOS, DXC and YELP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.

Zacks Equity Research

New Strong Buy Stocks for January 8th

by Zacks Equity Research

SONY, VVOS, DXC, LIND and FNCO have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.

Zacks Equity Research

All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy

by Zacks Equity Research

Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -3.01% and 0.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here Is Why Bargain Hunters Would Love Fast-paced Mover Vivos Therapeutics, Inc. (VVOS)

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Here's Why Vivos Therapeutics, Inc. (VVOS) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Vivos Therapeutics, Inc. (VVOS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Looking for a Fast-paced Momentum Stock at a Bargain? Consider Vivos Therapeutics, Inc. (VVOS)

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vivos Therapeutics, Inc. (VVOS) delivered earnings and revenue surprises of -17.65% and 3.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 12.50% and 3.97%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -7.50% and 175%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 12.99% and 94.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 11.76% and 2.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Exscientia PLC Sponsored ADR (EXAI) delivered earnings and revenue surprises of -72.73% and 47.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Impel Pharmaceuticals Inc. (IMPL) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -50.57% and 40.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Chinook Therapeutics (KDNY) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Chinook (KDNY) delivered earnings and revenue surprises of -33.87% and 614.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 2.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?